Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
Human Topoisomerase II alpha ELISA Kit for Sandwich ELISA - ABIN417527
Kumar, Ravi, Verma, Fatima, Hasanain, Singh, Sarkar, Luqman, Chanda, Negi: Synthesis of pharmacologically important naphthoquinones and anticancer activity of 2-benzyllawsone through DNA topoisomerase-II inhibition. in Bioorganic & medicinal chemistry 2017
Rat (Rattus) Topoisomerase II alpha ELISA Kit for Sandwich ELISA - ABIN431818
Xu, Chen, Wang, Xu, Yuan, Li, Bai, Xue: Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II. in Journal of experimental & clinical cancer research : CR 2016
Polyamide functionalisation at the N1-position offers a design strategy to improve drug-like properties. Dicationic HxIP* 3 increased topo IIalpha expression and chemosensitivity to topo II (show TOP2 ELISA Kits)-targeting agents.
We demonstrated that Nup98 (show NUP98 ELISA Kits)-TopIIbeta and Nup98 (show NUP98 ELISA Kits)-SETBP1 (show SETBP1 ELISA Kits) negatively regulate the XPO1 (show XPO1 ELISA Kits)-mediated protein export. Our results will contribute to the understanding of the molecular mechanism by which the Nup98 (show NUP98 ELISA Kits)-fusion proteins induce tumorigenesis.
TOP2 (show TOP2 ELISA Kits) and BAF (show BANF1 ELISA Kits) cooperate to recruit pluripotency factors, which explains some of the instructive roles of BAF (show BANF1 ELISA Kits) complexes.
Deletion or deficiency of PTEN leads to down regulation of TOP2A, dysfunction of the decatenation checkpoint and incomplete DNA decatenation in G2 and M phases.
Inhibition of DNA topoisomerase II (show TOP2 ELISA Kits) selectively reduces the threat of tumorigenicity
Cohesin removal is a prerequisite for the posterior topoisomerase IIalpha-mediated resolution of persisting catenations between segregating chromatids during anaphase II.
Data show that unfolded protein response (UPR)-induced changes in topoisomerase IIalpha (Topo IIalpha) protein levels are not responsible for resistance to etoposide, and that the PERK plays a Topo IIalpha-independent role in altered sensitivity to the drug.
TOP2beta (show TOP2B ELISA Kits) as a factor involved in regulating granulosa cell genomic integrity and follicle atresia.
Topoisomerase IIa not only contributes to stem-cell transcriptome regulation but also primes developmental genes for subsequent activation upon differentiation.
studies indicate that the ability of TOP2A to prevent DNA entanglement at mitosis requires BAF (show BANF1 ELISA Kits) complexes and suggest that this activity contributes to the role of BAF (show BANF1 ELISA Kits) subunits as tumour suppressors
These findings reveal a novel, p53 (show TP53 ELISA Kits)-independent activity of Mdm2 (show MDM2 ELISA Kits) and have important implications for the choice of chemotherapeutic agents in the treatment of Mdm2 (show MDM2 ELISA Kits)-overexpressing tumors. Herein is shown that tumor cells with MDM2 (show MDM2 ELISA Kits) amplification are selectively resistant to treatment with topoisomerase II (show TOP2 ELISA Kits) poisons but not other DNA damaging agents
The methodology is useful for a high-throughput analysis of drugs that poison Top2, allowing not just the discrimination of the Top2 isoform that is targeted but also to track its removal
TOP2A was identified in association with the progression and prognosis of pancreatic ductal adenocarcinoma probably by regulating cell cycle and p53 (show TP53 ELISA Kits) signaling pathway.
the relation between TOP2A levels and sensitivity for doxorubicin was examined, confirming reports that TOP2A mRNA levels were overexpressed in MPNST and showing that MPNST cell lines exhibited relatively high TOP2A protein levels and sensitivity to doxorubicin.
The decatenation checkpoint is regulated, not only by topo IIalpha, as previously reported, but also by topo IIbeta. The decatenation checkpoint is most efficient when both isoforms are present. Deletion of most of the C-terminus of topo IIalpha, while preserving the nuclear localization signal (NLS (show ALDH1A2 ELISA Kits)), enhances the decatenation checkpoint and sensitivity to topo II (show TOP2 ELISA Kits)-targeted drugs. Mutation of Y640 in topo IIalpha inhibi...
Tumors with higher topoisomerase IIalpha and/or mitosin (show CENPF ELISA Kits) expression have a higher risk of recurrence after initial treatment, and these patients may benefit from adjuvant treatment and closer radiological follow-up
Both the genome instability and cell death of MRE11 (show MRE11A ELISA Kits)-null and MRE11 (show MRE11A ELISA Kits)-mutated H129N cells are significantly reversed by overexpression of Tdp2 (show TDP2 ELISA Kits), an enzyme that eliminates covalent Top2 conjugates; thus, the essential role of Mre11 (show MRE11A ELISA Kits) nuclease (show DCLRE1C ELISA Kits) activity is likely to remove the DNA lesions.
we show that TopoIIalpha forms protein-protein interactions with beta-catentin and TCF4 (show TCF4 ELISA Kits) and interacts with Wnt (show WNT2 ELISA Kits) response elements (WREs) and promoters of direct target genes of TCF (show HNF4A ELISA Kits) transcription, including: MYC (show MYC ELISA Kits), vimentin (show VIM ELISA Kits), AXIN2 (show AXIN2 ELISA Kits) and LEF1 (show LEF1 ELISA Kits)
This study shows that both survivin (show BIRC5 ELISA Kits) and TIIalpha are independent prognostic predictors in human grade II/III astrocytomas stratified for IDH1 (show IDH1 ELISA Kits)-mutation status
This gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. It catalyzes the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA. Two forms of this enzyme exist as likely products of a gene duplication event. The gene encoding this form, alpha, is localized to chromosome 17 and the beta gene is localized to chromosome 3. The gene encoding this enzyme functions as the target for several anticancer agents and a variety of mutations in this gene have been associated with the development of drug resistance. Reduced activity of this enzyme may also play a role in ataxia-telangiectasia.
DNA topoisomerase II, alpha isozyme
, DNA Topoisomerase II alpha
, DNA topoisomerase 2-alpha
, topoisomerase (DNA) 2 alpha
, DNA gyrase
, DNA topoisomerase (ATP-hydrolyzing)
, DNA topoisomerase II, 170 kD
, DNA topoisomeraseII_alpha
, DNA topoisomerase 2-beta
, DNA topoisomerase II, beta isozyme